Status:
COMPLETED
Comorbidity Burden and Use of Concomitant Medications at CML Diagnosis
Lead Sponsor:
Polish Adult Leukemia Group
Conditions:
Chronic Myeloid Leukemia
Eligibility:
All Genders
18+ years
Brief Summary
The aim of the retrospective study was to further characterize the prevalence of comorbid conditions as well as the use of concomitant medications in newly diagnosed CML patients in a real-world setti...
Detailed Description
All three TKIs used as first line treatment of CML, (imatinib, dasatinib and nilotinib), may be associated with the so called "off-target" effects causing specific adverse events (AEs). Interestingly...
Eligibility Criteria
Inclusion
- 1\) age ≥ 18 years; 2) diagnosis of chronic phase CML between January 1st 2005 and December 31st 2014.
Exclusion
- primary diagnosis of CML in accelerated or blastic phase
Key Trial Info
Start Date :
February 1 2016
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
August 1 2016
Estimated Enrollment :
527 Patients enrolled
Trial Details
Trial ID
NCT06042660
Start Date
February 1 2016
End Date
August 1 2016
Last Update
September 18 2023
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.